TruScreen Rights Issue Offer Closing Soon

NZX/ASX Announcement


13 March 2023

Truscreen Renounceable Rights Issue Offer Closing Soon

Truscreen Group Limited (NZX/ASX:TRU) wishes to advise Shareholders that the one for five
Renounceable Rights Issue Offer will close on Wednesday, 15 March 2023 at 5pm NZ time (3pm
AEST).
For the latest market announcements and details of the Offer, please visit.
www.Truscreen.com
In the event shareholders have not received application forms please contact the share registry Link
Market Services:
enquiries@linkmarketservices.co.nz
T 64 9 375 5998 or the Company Secretary, contact details
below.
This announcement has ben approved by the Board.
Ends
Guy Robertson
Company Secretary
Tel: +61 407 983 270
Email: guyrobertson@truscreen.com


For more information, visit www.truscreen.com or contact:

Dr Beata Edling
Chief Executive Officer
beataedling@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Julia Maguire
Investor Relations
julia@thecapitalnetwork.com.au

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that
has developed an AI-enabled device that can detect precancerous and cancerous cervical changes
in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening
technologies that have only triage/adjunct functionality, the TruScreen device is registered as a
primary screening tool.
TruScreen’s cervical screening technology effectively resolves many of the ongoing issues with
conventional cytology, including failed samples, poor patient follow-up, patient discomfort, and the
need for supporting laboratory infrastructure.
The device is CE-marked, meaning it meets EU safety, health and environmental protection standards
required for sale and use throughout Europe. It is also National Medical Products Administration
approved for sale in China. In 2021, TruScreen established a manufacturing facility in China for
devices marketed and sold in China.
TruScreen is currently targeting product sales to a range of low and middle-income countries,
including China, Mexico, Vietnam, Russia, Zimbabwe and Saudi Arabia, where no large-scale cervical
cancer screening programmes and infrastructure are currently in place. By doing so, the Company
hopes to help improve the health and wellbeing of women worldwide.
To learn more, please visit: www.truscreen.com/